Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES NEW PRIVATE PLACEMENT OFFERING

Kane Biotech Inc. intends to undertake a non-brokered private placement offering of up to 20 million units of the company at a price of five cents per unit for gross proceeds of up to $1-million. Each unit shall be comprise one common share of the company and one share purchase warrant. Each full warrant shall entitle the holder thereof to purchase one additional share of the company for a period of 18 months at an exercise price of six cents per share.

After a period of four months from the closing date of the offering, in the event that the shares traded on the TSX Venture Exchange have a closing price at or exceeding nine cents per share for five consecutive trading days, the company reserves the right to call the warrants, at their exercise price of six cents per warrant. If the company wishes to call the warrants, the company must provide written notice to the holders of the warrants that it is calling the warrants. Investors will have 30 days from the date of such notice to exercise the warrants and, in the event that any warrants are not exercised, such warrants shall be cancelled.

The net proceeds of the offering will be used for working capital and general corporate purposes. Certain insiders of Kane Biotech may participate in the offering. Closing of the offering is expected to take place in the coming days.

All shares issued in connection with the offering are subject to a hold period of four months and one day from the date of issuance.

The offering is subject to receipt of all necessary approvals, including the approval of the TSX-V.

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser are all United States FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved.

We seek Safe Harbor.